(Methyl-1'-cyclohexyl)-3-propionsaeure | 28239-31-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Methyl-1'-cyclohexyl)-3-propionsaeure
• 英文别名: 3-(1-Methylcyclohexyl)propanoic acid
• CAS: 28239-31-8
• 化学式: C₁₀H₁₈O₂
• 分子量: 170.252
• InChiKey: WWGYGNYGUJOMQR-UHFFFAOYSA-N

物化性质

• 沸点：
  129-130 °C(Press: 2 Torr)
• 密度：
  0.980±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(1-甲基环己基)乙醇 在 硫酸 、 过氧化苯甲酰 作用下， 生成 (Methyl-1'-cyclohexyl)-3-propionsaeure
  参考文献：
  名称：

  Francois,H. et al., Bulletin de la Societe Chimique de France, 1970, # 2, p. 617 - 624

  摘要：

  DOI：

文献信息

• [EN] HERPES RIBONUCLEOTIDE REDUCTASE INHIBITORS<br/>[FR] INHIBITEURS DE LA RIBONUCLEOTIDE REDUCTASE DE L'HERPES
  申请人：BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE.

  公开号：WO1997000855A1

  公开（公告）日：1997-01-09

  (EN) Disclosed herein are compounds of formula (I) wherein R1 is hydrogen or (1-4C)alkyl, R2 is (1-4C)alkyl or a therapeutically acceptable salt thereof. The compounds are useful for treating herpes infections.(FR) Composés de formule (I) dans laquelle R1 représente hydrogène ou alkyle (C1-C4), R2 représente alkyle (C1-C4) ou un de ses sels acceptables thérapeutiquement. Ces composés sont utiles pour le traitement d'infections herpétiques.

  （中）本文公开了式（I）的化合物，其中R1为氢或（1-4C）烷基，R2为（1-4C）烷基或其治疗上可接受的盐。这些化合物可用于治疗疱疹感染。
• 3-CARBAMOYL-2-PYRIDONE DERIVATIVES
  申请人：ISHIZUKA Natsuki

  公开号：US20120208813A1

  公开（公告）日：2012-08-16

  The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R 1 , R 2 , R 3 , R 4 , and G are defined as herein, a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.

  本发明提供了具有激动大麻素受体的活性的化合物，该受体由公式（I）表示：其中R1、R2、R3、R4和G如本文所定义，其药学上可接受的盐或溶剂，以及制备该化合物为活性成分的药物组合物、治疗特应性皮炎的药剂和抗瘙痒剂，尤其是用于口服和外用的抗瘙痒剂。
• As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
  申请人：——

  公开号：US20020013304A1

  公开（公告）日：2002-01-31

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括给药含有有效量雄性激素的药物制剂，其中给药是按需给药，而不是长期药物治疗。局部给药可通过给药到个人的阴道、外阴部或尿道来实现，但对于那些口服活性的雄性激素制剂来说，口服给药是首选。此外，还提供了用于实施该方法的制剂和试剂盒。
• Treatment of dyspareunia with topically administered nitroglycerin formulations
  申请人：——

  公开号：US20040044080A1

  公开（公告）日：2004-03-04

  Methods and formulations for treating dyspareunia are provided. A pharmaceutical composition formulated so as to contain a therapeutically effective amount of nitroglycerin is administered to the vagina or vulvar area of the individual undergoing treatment. Preferred formulations are immediate release formulations in which at least 80% of the nitroglycerin in the formulation is released therefrom within 4 hours following administration. The formulations may contain one or more additional active agents, e.g., agents that are also useful to treat dyspareunia and/or potentiate the action of nitroglycerin. Such additional agents include vasoactive agents such as prostaglandins, phosphodiesterase inhibitors, androgens such as testosterone, estrogens such as estradiol, and selective modulators of estrogen and androgen receptors. A kit for a patient to use in the self-administration of the formulation is also provided.

  本研究提供了治疗性交困难的方法和制剂。将配制成含有治疗有效量硝化甘油的药物组合物施用到接受治疗者的阴道或外阴部位。首选的制剂是速释制剂，其中制剂中至少 80% 的硝酸甘油在给药后 4 小时内从制剂中释放出来。制剂可含有一种或多种额外的活性剂，例如，也可用于治疗性交困难和/或增强硝酸甘油作用的制剂。此类附加制剂包括血管活性剂，如前列腺素、磷酸二酯酶抑制剂、雄激素，如睾酮、雌激素，如雌二醇，以及雌激素和雄激素受体的选择性调节剂。此外，还提供了一种供患者用于自行服用制剂的试剂盒。
• As-needed administration of an androgenic agent to enhance female desire and responsiveness
  申请人：Wilson F. Leland

  公开号：US20050070516A1

  公开（公告）日：2005-03-31

  A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

  提供了一种提高女性性欲和性反应能力的方法。该方法包括给药含有有效量雄性激素的药物制剂，其中给药是按需给药，而不是长期药物治疗。局部给药可通过给药到个人的阴道、外阴部或尿道来实现，但对于那些口服活性的雄性激素制剂来说，口服给药是首选。此外，还提供了用于实施该方法的制剂和试剂盒。